Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-based evaluation of 8 mg aflibercept in neovascular age-related macular degeneration with pigment epithelial detachment
ChiCTR2600127294Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in age-related macular degeneration (AMD), sponsored by West China Hospital of Sichuan University. Primary endpoints: Mean change in central subfield thickness from baseline to month 12, Mean change in maximum pigment epithelial detachment height from baseline to month 12 and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on ChiCTR2600127294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127294.